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Abstract
Background: Specialized adult care of phenylketonuria (PKU) patients is of increasing importance. Adult outpatient
clinics for inherited errors of metabolism can help to achieve this task, but experience is limited. Ten years after
establishment of a coordinated transition process and specialised adult care for inherited metabolic diseases, adult
PKU care was evaluated with respect to metabolic control, therapy satisfaction, life satisfaction, sociodemographic
data, economical welfare as well as pregnancy outcome.
Methods: All PKU patients transferred from paediatric to adult care between 2005 and 2015 were identified. A
retrospective data analysis and a cross-sectional survey in a sub-cohort of 30 patients including a questionnaire for
assessing quality of life (FLZm) were performed as a single-centre investigation at the metabolic department of the
University Hospital Leipzig, Germany. For statistical analysis, Mann-Whitney-U-test, t-test for independent samples,
ANOVA and chi square test were used as appropriate.
Results: 96 PKU patients (56 females/40 males; median age 32 years, range 18–62) were included. In the last 3-year
period, 81 % of the transferred patients still kept contact to the adult care centre. Metabolic control was stable over
the evaluation period and dried blood phenylalanine concentrations mostly remained within the therapeutic range
(median 673.0 μmol/l, range 213.0–1381.1). Sociodemographic data, economical welfare and life satisfaction data
were comparable to data from the general population. However, differences could be revealed when splitting the
cohort according to time of diagnosis and to management during childhood. 83 % of the PKU adults were satisfied
with the transition process and current adult care. 25 completed pregnancies were supervised; three newborns,
born after unplanned pregnancy, showed characteristic symptoms of maternal PKU syndrome.
Conclusions: Continuous care for adult PKU patients in a specialized outpatient clinic is successful, leading to good
to satisfactory metabolic control and social outcomes. Uninterrupted good metabolic treatment throughout childhood
and adolescence positively influences educational, professional and economic success in later life. Further effort
in specialized paediatric and adult metabolic care is needed to prevent loss of follow-up and to support the
recommended life-long treatment and/or care.
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Background
The need for consistent life-long care for chronically ill
patients with special health care issues is increasingly rec-
ognized and requires further attention and development
[1]. Especially the transition of adolescents from paediatric
to adult health care is highly vulnerable [2–4]. They face
new responsibilities for their own health care, calling for
personal initiative and independence with respect to their
disease management. In this situation, they are at risk
to drop out of medical care [5, 6]. This is especially true
for patients with inherited metabolic diseases, such as
phenylketonuria (PKU; OMIM 261600) [7–9]. So far, the
majority of adults with PKU are still treated in paediatric
centres [8]; specialized adult centres are rare [8, 9]. Current
guidelines recommend life-long treatment and medical
attention to obtain the best possible neurologic outcome
and to avoid comorbidities [10–12]. In addition, with an
increasing number of PKU patients reaching reproductive
age, the prevention of maternal PKU syndrome, a severe
embryopathy affecting the unborn child of insufficiently
controlled PKU mothers, is of increasing importance [13].
To overcome these challenges, an adult outpatient clinic
and a coordinated transition process for patients with
inherited errors of metabolism was established in 2005 in
a cooperation of the paediatric outpatient clinic and the
department of internal medicine at the University Hospital
of Leipzig, Germany [9]. Since then, all patients 18 years
and older with inherited metabolic diseases were trans-
ferred from paediatric to adult care. The adult metabolic
care includes regular clinic visits and laboratory controls
as well as dietary counselling and educational training.
The aim of this study was to evaluate the appropriate-
ness of specialized adult metabolic care 10 years after its
establishment. For this purpose, we retrospectively ana-
lysed medical records with respect to metabolic control,
frequency of clinic visits, and adherence to treatment.
Also, data on pregnancies and pregnancy outcome as well
as sociodemographic data and educational status were
recorded. In addition, a cross-sectional survey was per-
formed regarding current therapy, life satisfaction and
satisfaction with the transition process and adult care.
Methods
Patients
All PKU patients transferred from paediatric to adult care
between 2005 and 2015 and followed in the adult out-
patient clinic for inherited metabolic diseases, University
of Leipzig, Germany were identified and included in the
data analysis. Sociodemographic data as well as metabolic
data and frequency of clinic visits were retrieved from
medical records and analysed retrospectively. For
better interpretation, all included patients were di-
vided into three groups, according to the time of diag-
nosis and treatment regime: group A was diagnosed
before implementation of newborn screening or beyond
newborn period (age range 3 months to adulthood), group
B was diagnosed by newborn screening (≤4 weeks of age)
and treated early, with therapy interruption during child-
hood and adolescence for more than 4 years (start of
interruption between 7–14 years of age, according to prior
guidelines, effective in the German Democratic Republic
[14]), and group C was diagnosed by newborn screening
(≤4 weeks of age) and continuously treated throughout
childhood and adolescence.
In addition, all completed pregnancies in PKU mothers
over the evaluation period were recorded.
As an extension of the evaluation, a survey was per-
formed in a sub-cohort. Inclusion in this survey was re-
stricted to PKU patients with a minimum age of 18 years,
confirmed diagnosis of PKU and therapy from the neo-
natal period (with or without interruption during child-
hood). Patients with other severe chronic diseases (i.e.
metabolic diseases, epilepsy), concomitant oral medica-
tion except the phenylalanine (Phe) free amino acid
mixture (AAM), or implementation of other diets except
the PKU diet were excluded to avoid confounding effects.
Also, PKU women currently pregnant or planning preg-
nancy were excluded from the survey for the same reason.
The study followed the principles of the guidelines in
the World Medical Association Declaration of Helsinki of
1975, as revised in 2000 and the harmonised ICH-Guideline
for Good Clinical Practice. It was approved by the University
of Leipzig’s ethics committee (registration number 440-12-
17122012) and registered at the International Clinical
Trials Registry Platform (DRKS00004942). Patients who
participated in the survey gave written informed consent.
Metabolic control
To evaluate patients’ metabolic control, their annual in-
dividual average Phe concentrations in dried blood after
transfer were calculated retrospectively. Every year, all
patients with at least one contact with the metabolic centre
(dried blood sample and/or clinic visit) were included in
the final analysis. Analysis of Phe concentrations from dried
blood spots was performed by liquid chromatography/
tandem mass spectrometry (LC-MS/MS) as described [15].
Survey
Between January 2013 and September 2015, all patients at-
tending the outpatient clinic were screened for participation
in the cross-sectional survey. Based on the questionnaire
used in a prior transition study [9], a questionnaire was
developed covering sociodemographic data (parenthood,
educational achievement, employment, and net income),
data on therapy management, dietary habits and metabolic
control as well as satisfaction with transition and special-
ized adult care.
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In addition, life satisfaction was assessed by “Questions
on Life Satisfaction” (FLZm) [16], a standardised and
validated questionnaire comprising the eight dimensions:
friends, recreational activities, health, income/financial
security, profession/work, domestic circumstances, fam-
ily life/children, partnership/sexuality. In the evaluation
process, the ratings for importance and satisfaction within
the different dimensions are combined to receive infor-
mation about weighted satisfaction, varying between -12
and +20 points. Global life satisfaction corresponds to the
sum of the weighted satisfaction values with a maximum
of 160 points.
Statistical analysis
All statistical analyses were performed using SPSS for
Windows 20 (SPSS Inc., Chicago, IL). Data are presented
as median and range or as mean and standard deviation
(SD), depending on data distribution. Mann-Whitney-
U-test or t-test for independent samples were used to
compare two groups. When more than two groups were
compared, ANOVA was applied (with post-hoc Bonferroni
test). Categorical data were analysed using the Chi square
test. Significance was accepted for P < 0.05.
Results
Patients
Between October 2005 and March 2015, 96 adults with
PKU (56 females/40 males; median age at time of ana-
lysis 32 years, range 18–62) were transferred from paedi-
atric to specialized adult care.
The total number of patients with contact to the out-
patient clinic slightly varied from year to year. In the past
3-year period, 81 % (44 females/32 males) of the transferred
patients kept contact to the adult outpatient clinic. Contact
was completely lost in 18 transferred patients. Seven of
them informed us that they attended specialized care in a
different centre due to vocational training or professional or
personal reasons. No information was available for the
remaining 11 patients despite regular effort to contact them.
Metabolic control
The median of individual mean dried blood Phe concen-
trations of all transferred PKU patients did not differ over
the 10-year period (673.0 μmol/l, range 213.0–1381.1) and
dried blood Phe concentration was within the therapeutic
range (according to the current recommendations for the
German speaking countries [17]) most of the time. Phe
concentrations were not significantly different between
females and males. Median dried blood tyrosine concentra-
tions (58.5 μmol/l, range 29.2–152.8) indicated an adequate
supply. Dividing the cohort into the three groups (A, B, C)
revealed some differences in metabolic control. Early diag-
nosed and continuously treated patients (group C) showed
better metabolic control throughout the observation period
than those with therapy interruption during childhood
(group B). Interestingly, these differences were present
(reaching statistical significance: P = 0.011 [ANOVA],
driven by the difference of groups B and C: P = 0.016
[Bonferroni]) at the age of 6 years, i.e. even before treat-
ment regimes diverged. Late diagnosis (group A) and
therefore late introduction of the strict dietary treatment
does not preclude good metabolic control (Table 2).
Since 2005, 25 completed pregnancies were supervised.
Three newborns, born after unplanned pregnancy, showed
characteristic symptoms of maternal PKU syndrome
(Table 1). PKU patients with unplanned pregnancies ex-
hibited significantly higher dried blood Phe concentra-
tions than women with planned pregnancies (P < 0.001)
and had significantly fewer contacts with the metabolic
centre (visits and/or dried blood samples).
Sociodemographic data
The majority of the adult PKU patients lived in the
German federal state of Saxony, at distances up to 400 km
from the metabolic centre. Sociodemographic data of the
PKU cohort are shown in Table 2 in comparison to the
annual statistics of Saxony for 2014 [18, 19]. While a
slightly higher proportion of PKU patients quit school
without formal graduation, educational attainment was
similar to that of the general population. Income tended
to be lower in PKU patients. Subgroup analysis showed
that the majority of patients diagnosed late (group A)
attended schools for special education and only one of
these patients completed an apprenticeship. Patients
without therapy interruption (group C) reached higher
graduation levels, and even a slightly higher proportion
achieved university graduation, as compared to the gen-
eral population; presumably due to the sample size, chi
square test was non-significant. PKU did not discourage
patients from establishing a family, independent of prior
therapy management. No parenthood was documented in
the group of late diagnosed PKU so far.
Table 1 Metabolic control of PKU females during pregnancy, comparing dried blood Phe concentrations in planned and unplanned
pregnancies (Mann-Whitney U-test)
Metabolic control during pregnancy planned n = 16 unplanned n = 9 P
Median (range) number of laboratory controls 36 (17–47) 17 (1–30) <0.001
Median (range) dried blood Phe concentration μmol/l 181 (101–485) 476 (172–878) <0.001
Offspring with clinical signs of maternal PKU syndrome 0 3
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Survey
During the survey period (January 2013 until September
2015), 67 patients attended the clinic at least once. Of
these, 46 PKU patients fulfilled the inclusion criteria and
were asked to participate, 21 were excluded due to late
diagnosis (n = 5), comorbidities (n = 9) or pregnancy and
pregnancy planning (n = 7). A total of 30 patients (17 fe-
males/13 males; median age 32 years, range 18–43)
responded to the survey.
Results of the survey are presented in Table 3. Pa-
tients currently on diet showed significantly lower
mean dried blood Phe concentrations (n = 22; 637 ±
212 μmol/l, range 282–1072) compared to patients off
diet (n = 8, 842 ± 174 μmol/l, range 530–1118, P =
0.015, dried blood Phe concentrations 1 year prior
evaluation). Median tyrosine concentrations were
significantly higher in patients on diet compared to
patients off diet (66.9 μmol/l, range 37.0–162.5 vs
42.1 μmol/l, range 32.8–67.4, P = 0.006). Interestingly,
all but two patients off diet belonged to the group
with therapy interruption of at least 4 years during
childhood.
Table 2 Sociodemographic data and metabolic control of the investigated adult PKU cohort as well as for subgroups (group A = late
diagnosed patients; group B = early diagnosed + therapy interruption≥ 4 years during childhood/adolescence; group C = early diagnosed
and continuously treated) compared to the reference population of German federal state of Saxony [18, 19]. Graduations: modern
certificate (i.e. at the age of 15 years; after 9 years of school), secondary school certificate (i.e. at the age of 16 years; after 10 years
of school), high school diploma (i.e. at the age of 18–19 years; after 12–13 years of school). The number of PKU patients per
characteristic varies, as not all data of all patients were available
PKU patients total
(n = 96)
Group A (n1 = 8) Group B (n1 = 29) Group C (n1 = 59) Population of
Saxony 2014
Current median age (range) in years 32 (18–62) 32 (19–62) 39 (34–46) 30 (18–44) n.a.
Number currently on/off diet (n) 76/20 6/2 21/8 49/10 n.a.
Graduation n2 = 90 n2 = 7 n2 = 28 n2 = 55
no graduation/special education [%] 14.5a 85.7 10.7 3.6 8.7
secondary modern school certificate [%] 18.9 14.3 28.6 18.2 9.9
secondary school certificate [%] 43.3 0.0 50.0 45.5 52.0
high school diploma [%] 23.3 0.0 10.7 32.7 29.4
Educational attainment n2 = 85 n2 = 7 n2 = 28 n2 = 51
Apprenticeship [%] 77.6 14.3 89.3 76.5 77.2
University degree [%] 12.9 0.0 7.1 17.6 14.5
Without [%] 10.6a 85.7 3.6 5.9c 8.3
Net income (per month) n2 = 24b n.a. n2 = 8b n2 = 16b
<700€ 20.8 12.5 25.0 13.0
700€–1500€ 50.0 62.5 43.8 53.5
>1500€ 29.2 25.0 31.2 33.5
Parenthood [%] n2 = 78 n2=80.0 n2 = 23 n2 = 48 41.0
41.0 56.5 39.6
Metabolic control
Median (range) dried blood Phe concentration
during the 6th year of life [μmol/l]
n2 = 74 n2 = 3 n2 = 23 n2 = 48 n.a.
307.3 (92.1–1246.6) 203.9 (192.9–289.7) 447.0 (107.9–
1246.6)
263.6 (92.1–901.9)
Median (range) dried blood Phe concentration
during the 18th year of life [μmol/l]
n2 = 71 n2 = 4 n2 = 19 n2 = 48 n.a.
587.4 (52.5–1454.6) 650.2 (434.8–
1247.0)
622.3 (169.7–
1454.6)
562.6 (52.5–1186.6)
Current median (range) dried blood Phe
concentration (last three values) [μmol/l]
n2 = 96 n2 = 8 n2 = 29 n2 = 59 n.a.
658.7 (109.1–
1458.5)
617.9 (323.4–
1209.7)
789.0 (109.1–
1458.5)
596.2 (168.1–
1365.2)
n1: all retrospectively analysed patients
n2: patients with available data
n.a. not applicable
aincludes late diagnosed PKU patients with special school education and patients still in education
bdata available only for the participants of the survey (n = 30)
cin total three patients, two of them are still trainees
Mütze et al. Orphanet Journal of Rare Diseases  (2016) 11:27 Page 4 of 8
Twenty-seven participants (16 females/11 males) an-
swered the “Questions on Life Satisfaction”, three
declined. The respondents’ mean score was 66.7 ±
31.7 points, compared to an average value of the
German population of 62.7 ± 37.1 points (age group
18 to 45 years) [16]. The higher score in PKU females
was not statistically different from their male counter-
parts (70.2 ± 36.5 vs. 61.6 ± 23.7 points; P = 0.468).
Patients on diet exhibited higher scores of life satis-
faction compared to patients off diet (72.9 ± 33.9 vs.
52.0 ± 20.5 points, P = 0.062).
Table 3 Therapy management and satisfaction (single centre
survey; n = 30; 17 females/13 males). A Clinic visits, laboratory
controls and dietary treatment. B Transition satisfaction and
coping with treatment
A: Clinic visits, laboratory controls and dietary treatment
Frequency of laboratory controls/dried blood samples n %
Monthly 13 43.3
Every two month 5 16.7
Quarterly 5 16.7
Biannually 3 10.0
Annually 2 6.7
No answer 2 6.7
Frequency of clinic visits
Quarterly 11 36.7
Three times a year 2 6.7
Biannually 12 40.0
Annually 4 13.3
No visits 1 3.3
Dietary treatment
Phe/protein restricted diet 22 73.3
Exact calculating Phe content 4 12.3
Estimation of Phe content 16 53.3
No strict diet regime/vegetarian diet 2 6.6
Amino acid mixture (AAM) 24 80.0
BH4 0 0
Discontinuation of the PKU treatment
Never 14 46.7
Once 7 23.3
Several times 5 16.7
No answer 4 13.3
Reasons for discontinuation of the PKU treatment (n = 12)
Stop of dietary treatment in adolescence
according to former procedures
3 25.0
Weariness to follow the diet/Wish for
independence from treatment
5 41.7
Good metabolic control following a
vegetarian diet
3 25.0
No answer 1 8.3
Restart of the PKU treatment 10 83.3
Reasons for restart of the PKU treatment (n = 10)
Doctors recommendation 2 20.0
More capability/long-term prevention 2 20.0
Wish to become pregnant/pregnancy 4 40.0
No answer 2 20.0
Table 3 Therapy management and satisfaction (single centre
survey; n = 30; 17 females/13 males). A Clinic visits, laboratory
controls and dietary treatment. B Transition satisfaction and
coping with treatment (Continued)
B: Transition satisfaction and coping with treatment.
Satisfaction with the actual individual metabolic control n %
Very satisfied 10 33.3
Satisfied 14 46.7
Less satisfied 5 16.7
Not satisfied 0 0
No answer 1 3.3
Personal importance of good metabolic control
Very important 12 40.0
Important 14 46.7
Less important 3 10.0
Not important 0 0
No answer 1 3.3
Current coping with dietary therapy
Very well 10 33.3
Well 13 43.3
Moderately 2 6.7
Badly 1 3.3
No answer 4 12.3
Coping with dietary treatment in adulthood in comparison to
childhood
Easier 13 43.3
Indifferent 8 26.7
More difficult 5 16.7
No answer 4 12.3
Satisfaction with transition process and adult care
Very satisfied 10 33.3
Satisfied 15 50.0
Less satisfied 0 0
Not satisfied 3 10.0
No answer 2 6.7
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Discussion
Transition from paediatric to adult health care is a
particularly vulnerable period for patients with inher-
ited metabolic diseases [20]. Data revealed so far
show the need for a special education in inherited
metabolic diseases for adult health care providers, new
guidelines for adult patients, and an improvement of
the structures for transition [7–9, 11, 21]. Most PKU
adults are cared for in paediatric centres [8] and there
are only few specialized adult outpatient clinics. There-
fore, only limited data about PKU adult care are
available. In 2005, a transition program and out-
patient clinic for adults with inherited metabolic
diseases was established in Leipzig [9]. Now, a retro-
spective data analysis and cross-sectional survey
evaluating the first 10 years of specialized adult PKU
care was performed.
Analysing clinical practice in a specialized adult out-
patient clinic for inherited metabolic diseases over a
10-year period, 81 % of the transferred PKU patients still
kept contact to the adult care centre in the last 3 years.
Metabolic control was stable over the evaluation period
and dried blood Phe concentrations mostly remained
within the therapeutic range [17]. Overall sociodemo-
graphic, economic and life satisfaction data were compar-
able to the reference population and 83 % of the PKU
adults were satisfied with the transition process and
adult care.
Frequency of contact to the metabolic centre varied
widely. Some patients did not attend the clinic for
some time only to come back for regular care after a
while. Looking at 3-year periods, about 80 % of all
transferred patients had at least one contact. Due to
vocational training or professional and personal rea-
sons, some patients moved to other metabolic centres.
Less than 12 % appear to be lost to the specialized
care. These data indicate that a successful, continuous
follow-up of adult PKU patients is achievable. With a
median age of 32 years, our cohort extends previously
reported experience from an international survey of
adults with PKU, reporting outcomes at a median age
below 29 years [8].
During the 10-year follow-up, all supervised PKU
patients showed good metabolic control with individual
mean Phe concentrations within the therapeutic range
according to the current guidelines for the German
speaking countries [17]. No significant difference in
metabolic control during adulthood could be detected
with respect to age at diagnosis or therapeutic strategy
during childhood/adolescence. However, as expected,
the analysis of the survey yielded significantly higher Phe
concentrations in patients off diet compared to those on
diet. Patients with optimal metabolic control were also
those who attended the clinic more often (data not shown).
This indicates that realisation of recommended therapeutic
targets, which were shown to improve outcome [22, 23], re-
quires constant patient education. In light of the recently
updated US guidelines and the expected European guide-
lines, which both advocate even stricter metabolic targets,
this issue becomes even more important [23]. This stric-
ter recommendation might improve patients’ outcome,
but will also carry an even greater burden for the pa-
tients to successfully adhere to treatment. Former stud-
ies showed therapy adherence declined especially during
adolescence and adulthood [9, 24]. In the present survey,
half of the adult patients interrupted therapy at least once
over an extended period (>4 years). Reasons were former
guidelines in the eastern part of Germany, no longer in
place [14], but also the typical difficulties in treatment of
adolescents and young adults with chronic diseases.
Nevertheless, the majority of these patients restarted
therapy after picking up regular consultations in the
specialised metabolic centre.
Especially the supervision of PKU females in child-
bearing age represents a great challenge [13]. For this
group of patients, strict metabolic control with Phe con-
centrations between 120 and 360 μmol/l is indispensable
before and during pregnancy in order to prevent mater-
nal PKU syndrome [25]. The majority of the evaluated
pregnancies in this cohort were planned, well supervised
and, therefore, under good metabolic control, in accord-
ance to the current recommendation [25]. One-third of
the pregnancies, however, were unplanned and, therefore,
occurred under unfavourable metabolic conditions: in
unplanned pregnancies significantly higher Phe concen-
trations were recorded compared to planned pregnancies.
This again underscores the importance of specialized
adult care in PKU adults. All three children with mater-
nal PKU syndrome were born after unplanned pregnancy
with insufficient metabolic control [26]. Unfortunately,
the mothers refused to follow any of the recommenda-
tions, despite every effort by the metabolic team. Import-
antly, these documented cases of maternal PKU syndrome
might not be representative of the entire scope of
maternal PKU syndrome even in our cohort. Since clinic-
ally normal infants from PKU mothers are not routinely
followed up so far, the incidence of mild forms may be
underestimated [27].
Successful transition requires an experienced multi-
disciplinary team of paediatric and adult health care pro-
viders. The majority of the included patients were satisfied
with their transition process and care during the last
10 years and cope well with their therapy. For most, adher-
ence to therapy is easier as adults than during childhood.
However, especially female patients expressed the wish for
an even more intensive care, referring to dietary counsel-
ling, real-time information about Phe values and a closer
contact for following therapy adaptions (data not shown).
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Most of the survey participants still followed a Phe
restricted diet and took AAM, albeit not as strictly as
during childhood. Moreover, the majority reported good
metabolic control to be personally important and were
satisfied with their current metabolic control.
Regarding life satisfaction, all patients showed a good
general life satisfaction with a mean score above the score
of a German reference sample [16]. This is in accordance
with former findings in patients with PKU [9, 28]. One
might question the relevance of these data as the investi-
gated group is rather small. However, in order to exclude
potential confounding factors, strict inclusion criteria
were implemented. Life satisfaction of patients on diet
was higher with a score difference of 20 points com-
pared to patients off diet. Interestingly, patients on diet
scored higher than the general population mean, while
those off diet scored lower than the general population
mean by the same degree. Due to high variance of
scores in patients and the general population, these dif-
ferences missed significance. This important aspect of
therapy continuation is in accordance with a former study
reporting that patients’ quality of life improved after re-
introduction of a Phe-restricted diet [29]. The resumption
of the Phe-restricted diet, however, often represents a
great challenge for the patients as they show low therapy
adherence or terminate the diet again after a short while
[29]. Again, this supports the recommendations for con-
tinuous therapy and adult specialised care.
Social outcome acts as an important indicator for the
effective life-long treatment of inherited metabolic
diseases. In a previous study, we reported some minor
differences regarding school graduation compared to
the reference population [9]. This is in accordance with
similar studies by other groups [30–33]. Despite important
improvements in therapeutic management over the past
decades, differences of sociodemographic development
remain between PKU patients and the control population.
This depends not only on time of diagnosis, but also on
continuity of consistent treatment throughout childhood,
adolescence and the transition period. As expected,
patients diagnosed late did not visit regular school, and
consequently did not reach a general educational degree.
Early diagnosed patients who interrupted their treatment
during childhood and adolescence for several years per-
formed markedly poorer with respect to school graduation
and educational attainment. In contrast, early diagnosed
and continuously treated patients showed no differences
in socioeconomic data compared to the healthy popula-
tion. In some fields they even perform better, as shown by
the very low rate of these young PKU adults leaving school
without graduation.
The distribution of net income was comparable be-
tween early diagnosed PKU patients and the control co-
hort independent from therapy interruption. It improved
since 2008, correcting for inflation and the general eco-
nomic situation in the state of Saxony [9, 18, 19]. Fortu-
nately, and in contrast to former studies reporting rare
parenthood in adult PKU patients [9, 30], the percentage
of adults with PKU having children was comparable to the
reference population. PKU seems no longer to discourage
patients from establishing a family.
The cohort size of the survey was limited by strict inclu-
sion criteria. The lower percentage of patients on diet than
in our prior study (73 % vs. 92 %) [9] is influenced by ex-
clusion of women with planned or current pregnancies.
As always, a selection bias by inclusion of motivated pa-
tients must be considered, especially for the survey data.
The obvious limitation of a single-centre study can cur-
rently not be overcome since adult PKU centres are only
being established, so that comparable longitudinal data
are not available from other sites. Analysis of larger study
groups, once available, may add important and interesting
aspects.
Conclusion
Continuous care for adult PKU patients in a specialized out-
patient clinic is successful, leading to good to satisfactory
metabolic control and social outcomes. Uninterrupted con-
sistent metabolic treatment throughout childhood and ado-
lescence positively influences educational, professional and
economic success in later life. Despite enormous efforts,
prevention of maternal PKU syndrome remains a challenge.
Further effort in specialized paediatric and adult metabolic
care is needed to prevent loss of follow-up and to support
the recommended life-long treatment and/or care.
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